0 false false false false false false false false false false true false false false false false false 2024-04-01 Sage Accounts Production Advanced 2024 - FRS102_2024 939,699 368,910 443,332 865,277 35,604 45,931 81,535 946,812 975,303 xbrli:pure xbrli:shares iso4217:GBP 13536747 2024-04-01 2025-03-31 13536747 2025-03-31 13536747 2024-03-31 13536747 2023-04-01 2024-03-31 13536747 2024-03-31 13536747 2023-03-31 13536747 bus:RegisteredOffice 2024-04-01 2025-03-31 13536747 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 13536747 bus:Director1 2024-04-01 2025-03-31 13536747 bus:Director2 2024-04-01 2025-03-31 13536747 bus:Director3 2024-04-01 2025-03-31 13536747 bus:Director4 2024-04-01 2025-03-31 13536747 core:WithinOneYear 2025-03-31 13536747 core:WithinOneYear 2024-03-31 13536747 core:RevaluationReserve 2023-04-01 2024-03-31 13536747 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 13536747 core:RevaluationReserve 2024-04-01 2025-03-31 13536747 core:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 13536747 core:UKTax 2024-04-01 2025-03-31 13536747 core:UKTax 2023-04-01 2024-03-31 13536747 core:ShareCapital 2025-03-31 13536747 core:ShareCapital 2024-03-31 13536747 core:RevaluationReserve 2025-03-31 13536747 core:RevaluationReserve 2024-03-31 13536747 core:RetainedEarningsAccumulatedLosses 2025-03-31 13536747 core:RetainedEarningsAccumulatedLosses 2024-03-31 13536747 core:ShareCapital 2023-03-31 13536747 core:RevaluationReserve 2023-03-31 13536747 core:RetainedEarningsAccumulatedLosses 2023-03-31 13536747 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 13536747 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 13536747 core:DisposalsRepaymentsInvestments core:Non-currentFinancialInstruments 2025-03-31 13536747 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 13536747 core:Non-currentFinancialInstruments core:ProvisionsForImpairmentInvestments 2024-03-31 13536747 core:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal core:Non-currentFinancialInstruments 2025-03-31 13536747 core:Non-currentFinancialInstruments core:ProvisionsForImpairmentInvestments 2025-03-31 13536747 core:Non-currentFinancialInstruments 2025-03-31 13536747 core:Non-currentFinancialInstruments 2024-03-31 13536747 bus:SmallEntities 2024-04-01 2025-03-31 13536747 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 13536747 bus:SmallCompaniesRegimeForDirectorsReport 2024-04-01 2025-03-31 13536747 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13536747 bus:FullAccounts 2024-04-01 2025-03-31 13536747 bus:OrdinaryShareClass1 2025-03-31 13536747 bus:OrdinaryShareClass1 2024-03-31
COMPANY REGISTRATION NUMBER: 13536747
STRIDE PIV LTD
Unaudited Financial Statements
31 March 2025
STRIDE PIV LTD
Financial Statements
Year ended 31 March 2025
Contents
Page
Directors' report
1
Statement of comprehensive income
2
Statement of financial position
3
Statement of changes in equity
4
Statement of cash flows
5
Notes to the financial statements
6
STRIDE PIV LTD
Directors' Report
Year ended 31 March 2025
The directors present their report and the unaudited financial statements of the company for the year ended 31 March 2025 .
Principal activities
The principal activity of the company during the year was activities of open-ended investments.
Directors
The directors who served the company during the year were as follows:
Mr Dale Callum Peter Nursten
Ms Diane Kim Nursten
Ms Sally Nursten
Mr Scott Malcolm Erwin Nursten
Dividends
The directors do not recommend the payment of a dividend.
This report was approved by the board of directors on 12 September 2025 and signed on behalf of the board by:
Mr Dale Callum Peter Nursten
Director
Registered office:
B1 Vantage Park
Old Gloucester Road
Hambrook
Bristol
BS161GW
STRIDE PIV LTD
Statement of Comprehensive Income
Year ended 31 March 2025
2025
2024
Note
£
£
Turnover
4
448,527
195,392
Cost of sales
443,332
269,672
---------
---------
Gross profit/(loss)
5,195
( 74,280)
Administrative expenses
28,602
34,805
Other operating income
5
45,000
--------
---------
Operating profit/(loss)
6
21,593
( 109,085)
Income from other fixed asset investments
7
96,010
60,844
Other interest receivable and similar income
8
5,439
81
Interest payable and similar expenses
9
213
6,431
---------
---------
Profit/(loss) before taxation
122,829
( 54,591)
Tax on profit/(loss)
10
9,747
( 19,205)
---------
--------
Profit/(loss) after taxation
113,082
( 35,386)
Other taxes not shown under the above
3,922
4,497
---------
--------
Profit/(loss) for the financial year
109,160
( 39,883)
---------
--------
Fair Value Adjustments
45,931
166,334
---------
---------
Total comprehensive income for the year
155,091
126,451
---------
---------
All the activities of the company are from continuing operations.
STRIDE PIV LTD
Statement of Financial Position
31 March 2025
2025
2024
Note
£
£
Fixed assets
Investments
11
946,812
975,303
Current assets
Cash at bank and in hand
282,656
91,524
Creditors: amounts falling due within one year
12
1,038,804
1,031,254
------------
------------
Net current liabilities
756,148
939,730
---------
---------
Total assets less current liabilities
190,664
35,573
---------
--------
Capital and reserves
Called up share capital
13
4
4
Revaluation reserve
14
81,535
35,604
Profit and loss account
14
109,125
( 35)
---------
--------
Shareholders funds
190,664
35,573
---------
--------
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.
These financial statements were approved by the board of directors and authorised for issue on 12 September 2025 , and are signed on behalf of the board by:
Mr Dale Callum Peter Nursten
Director
Company registration number: 13536747
STRIDE PIV LTD
Statement of Changes in Equity
Year ended 31 March 2025
Called up share capital
Revaluation reserve
Profit and loss account
Total
£
£
£
£
At 1 April 2023
4
( 130,730)
39,848
( 90,878)
Loss for the year
( 39,883)
( 39,883)
Other comprehensive income for the year:
Fair Value Adjustments
166,334
166,334
----
---------
--------
---------
Total comprehensive income for the year
166,334
( 39,883)
126,451
At 31 March 2024
4
35,604
( 35)
35,573
Profit for the year
109,160
109,160
Other comprehensive income for the year:
Fair Value Adjustments
45,931
45,931
----
---------
---------
---------
Total comprehensive income for the year
45,931
109,160
155,091
----
---------
---------
---------
At 31 March 2025
4
81,535
109,125
190,664
----
---------
---------
---------
STRIDE PIV LTD
Statement of Cash Flows
Year ended 31 March 2025
2025
2024
£
£
Cash flows from operating activities
Profit/(loss) for the financial year
109,160
( 39,883)
Adjustments for:
Income from other fixed asset investments
( 96,010)
( 60,844)
Other interest receivable and similar income
( 5,439)
( 81)
Interest payable and similar expenses
213
6,431
Tax on profit/(loss)
9,747
(19,205)
Changes in:
Trade and other debtors
6,517
Trade and other creditors
98
30
---------
---------
Cash generated from operations
17,769
( 107,035)
Interest paid
( 213)
( 6,431)
Interest received
5,439
81
Tax received
19,205
--------
---------
Net cash from/(used in) operating activities
22,995
( 94,180)
--------
---------
Cash flows from investing activities
Purchases of other investments
(368,910)
(271,312)
Proceeds from sale of other investments
443,332
269,726
Proceeds from sale of futures contracts, forward contracts, option contracts and swap contracts
24,115
14,354
Dividends received
71,895
46,490
---------
---------
Net cash from investing activities
170,432
59,258
---------
---------
Cash flows from financing activities
Proceeds from borrowings
( 254,999)
Proceeds from loans from group undertakings
( 2,295)
452,233
---------
---------
Net cash (used in)/from financing activities
( 2,295)
197,234
---------
---------
Net increase in cash and cash equivalents
191,132
162,312
Cash and cash equivalents at beginning of year
91,524
(70,788)
---------
--------
Cash and cash equivalents at end of year
282,656
91,524
---------
--------
STRIDE PIV LTD
Notes to the Financial Statements
Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is B1 Vantage Park, Old Gloucester Road, Hambrook, Bristol, BS161GW.
2. Statement of compliance
These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Turnover
Turnover arises from:
2025
2024
£
£
Sale of goods
448,527
195,392
---------
---------
The whole of the turnover is attributable to the principal activity of the company wholly undertaken in the United Kingdom.
5. Other operating income
2025
2024
£
£
Other operating income
45,000
--------
----
6. Operating profit/(loss)
Operating profit or loss is stated after charging:
2025
2024
£
£
Foreign exchange differences
5,215
1,227
-------
-------
7. Income from other fixed asset investments
2025
2024
£
£
Dividends from other fixed asset investments
71,895
46,490
Other income from other fixed asset investments
24,115
14,354
--------
--------
96,010
60,844
--------
--------
8. Other interest receivable and similar income
2025
2024
£
£
Interest receivable
5,439
81
-------
----
9. Interest payable and similar expenses
2025
2024
£
£
Other interest payable and similar charges
213
6,431
----
-------
10. Tax on profit/(loss)
Major components of tax expense/(income)
2025
2024
£
£
Current tax:
UK current tax expense/(income)
9,747
( 19,205)
-------
--------
Tax on profit/(loss)
9,747
( 19,205)
-------
--------
Reconciliation of tax expense/(income)
The tax assessed on the profit/(loss) on ordinary activities for the year is lower than (2024: lower than) the standard rate of corporation tax in the UK of 25 % (2024: 19 %).
2025
2024
£
£
Profit/(loss) on ordinary activities before taxation
122,829
( 54,591)
---------
--------
Profit/(loss) on ordinary activities by rate of tax
30,707
( 10,372)
Other tax adjustment to increase/(decrease) tax liability
(20,960)
(8,833)
---------
--------
Tax on profit/(loss)
9,747
( 19,205)
---------
--------
11. Investments
Other investments other than loans
£
Cost
At 1 April 2024
939,699
Additions
368,910
Disposals
( 443,332)
---------
At 31 March 2025
865,277
---------
Impairment
At 1 April 2024
( 35,604)
Revaluations
( 45,931)
---------
At 31 March 2025
( 81,535)
---------
Carrying amount
At 31 March 2025
946,812
---------
At 31 March 2024
975,303
---------
12. Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
128
30
Amounts owed to group undertakings
1,028,929
1,031,224
Corporation tax
9,747
------------
------------
1,038,804
1,031,254
------------
------------
13. Called up share capital
Authorised share capital
2025
2024
No.
£
No.
£
Ordinary shares of £ 1 each
4
4
4
4
----
----
----
----
Issued, called up and fully paid
2025
2024
No.
£
No.
£
Ordinary shares of £ 1 each
4
4
4
4
----
----
----
----
14. Reserves
Share premium account - This reserve records the amount above the nominal value received for shares sold, less transaction costs. Revaluation reserve - This reserve records the value of asset revaluations and fair value movements on assets recognised in other comprehensive income. Capital redemption reserve - This reserve records the nominal value of shares repurchased by the company. Profit and loss account - This reserve records retained earnings and accumulated losses.
15. Analysis of changes in net debt
At 1 Apr 2024
Cash flows
At 31 Mar 2025
£
£
£
Cash at bank and in hand
91,524
191,132
282,656
Debt due within one year
(1,031,224)
2,295
(1,028,929)
------------
---------
------------
( 939,700)
193,427
( 746,273)
------------
---------
------------